Orexo AB is a specialty pharmaceutical company in the United States. Its launched products include Zubsolv sublingual tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. It has collaboration agreement with Mundipharma for the development and commercialization of Zubsolv and with AstraZeneca with regards to the OX-Cysteinyl Leukotriene Inhibitor project. Founded in 1995, the company is headquartered in Uppsala, Sweden.